Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.24)
# 4,383
Out of 5,182 analysts
17
Total ratings
20%
Success rate
-24.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INTS Intensity Therapeutics | Upgrades: Buy | $75 | $5.19 | +1,345.09% | 1 | Aug 12, 2025 | |
| PALI Palisade Bio | Maintains: Buy | $16 | $1.99 | +704.02% | 2 | May 13, 2025 | |
| QNCX Quince Therapeutics | Initiates: Buy | $90 | $1.33 | +6,666.92% | 1 | Dec 18, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $3.47 | +130.55% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $28.19 | +254.74% | 2 | May 30, 2024 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $0.26 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $3,750 | $1.55 | +241,835.48% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $0.73 | +1,954.79% | 1 | Jun 29, 2023 | |
| ATYR aTyr Pharma | Reinstates: Buy | $9 | $0.83 | +979.78% | 1 | Mar 6, 2023 | |
| RAIN Rain Enhancement Technologies Holdco | Reinstates: Buy | $21 | $2.17 | +867.74% | 1 | Jan 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $90 | $53.25 | +69.01% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $310 | $2.26 | +13,616.81% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33,600 | $1.33 | +2,526,215.79% | 1 | Sep 21, 2021 |
Intensity Therapeutics
Aug 12, 2025
Upgrades: Buy
Price Target: $75
Current: $5.19
Upside: +1,345.09%
Palisade Bio
May 13, 2025
Maintains: Buy
Price Target: $16
Current: $1.99
Upside: +704.02%
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $90
Current: $1.33
Upside: +6,666.92%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $3.47
Upside: +130.55%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $28.19
Upside: +254.74%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.26
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $3,750
Current: $1.55
Upside: +241,835.48%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $0.73
Upside: +1,954.79%
aTyr Pharma
Mar 6, 2023
Reinstates: Buy
Price Target: $9
Current: $0.83
Upside: +979.78%
Rain Enhancement Technologies Holdco
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $2.17
Upside: +867.74%
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $53.25
Upside: +69.01%
May 18, 2022
Maintains: Buy
Price Target: $290 → $310
Current: $2.26
Upside: +13,616.81%
Sep 21, 2021
Initiates: Buy
Price Target: $33,600
Current: $1.33
Upside: +2,526,215.79%